Shawnte Mitchell Insider Profile
4 Followers
Shawnte Mitchell, SVP, GC and Corporate Affairs at Aptevo Therapeutics, holds 80.53K shares in Aptevo Therapeutics (Ticker: APVO), holds ― shares in Zogenix (Ticker: ZGNX), holds 0.00 shares in Olema Pharmaceuticals (Ticker: OLMA).
Shawnte Mitchell has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Shawnte Mitchell holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Shawnte Mitchell
Shawnte Mitchell's Trading History
Aptevo Therapeutics
Mar 04, 2019
SVP, GC and Corporate Affairs
Uninformative Buy
7.50K
$343.85K
Zogenix
―
―
―
―
Olema Pharmaceuticals
Mar 05, 2026
CLO
Uninformative Buy
174.80K
$0.00
List of latest transactions for each holding click on a transaction to see Shawnte Mitchell's performance on stock
You May Also Like
Shawnte Mitchell insider profile FAQ
What is the percentage of profitable transactions made by Shawnte Mitchell?
The percentage of profitable transactions made by Shawnte Mitchell is ―.
What is the average return per transaction made by Shawnte Mitchell?
The average return per transaction made by Shawnte Mitchell is ―.
What stocks does Shawnte Mitchell hold?
Shawnte Mitchell holds: APVO, ZGNX, OLMA stocks.
What was Shawnte Mitchell’s latest transaction?
Shawnte Mitchell latest transaction was an Uninformative Buy of $7.50K.
What was Shawnte Mitchell's most profitable transaction?
Shawnte Mitchell’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Shawnte Mitchell's role in Aptevo Therapeutics?
Shawnte Mitchell's role in Aptevo Therapeutics is SVP, GC and Corporate Affairs.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.